Provided by Tiger Trade Technology Pte. Ltd.

Natera

207.98
+4.772.35%
Pre-market: 202.24-5.7400-2.76%08:41 EDT
Volume:1.28M
Turnover:265.94M
Market Cap:29.48B
PE:-136.60
High:210.99
Open:198.19
Low:198.02
Close:203.21
52wk High:256.36
52wk Low:125.38
Shares:141.73M
Float Shares:135.00M
Volume Ratio:1.18
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5225
EPS(LYR):-1.5269
ROE:-14.32%
ROA:-9.54%
PB:17.21
PE(LYR):-136.21

Loading ...

Natera CFO Michael Burkes Brophy Reports Disposal of Common Shares

Reuters
·
Oct 25, 2025

Natera’s Strong Position in MRD Market Bolstered by Signatera’s Impact and Potential FDA Approval

TIPRANKS
·
Oct 24, 2025

U.S. RESEARCH ROUNDUP-Blackstone, Ford, Intel

Reuters
·
Oct 24, 2025

TD Cowen Reaffirms Their Buy Rating on Natera (NTRA)

TIPRANKS
·
Oct 24, 2025

Natera Is Maintained at Buy by BTIG

Dow Jones
·
Oct 24, 2025

Natera price target raised to $210 from $200 at BTIG

TIPRANKS
·
Oct 24, 2025

Natera Executive Chairman Matthew Rabinowitz Reports Sale of Common Shares

Reuters
·
Oct 23, 2025

Natera Inc. President of Clinical Diagnostics Solomon Moshkevich Reports Disposal of Common Shares

Reuters
·
Oct 23, 2025

BRIEF-Natera Inc Says IMvigor011 Trial Achieves 41% Improvement In Overall Survival

Reuters
·
Oct 20, 2025

Does Natera's (NTRA) MRD Platform Recognition Signal Strengthening Competitive Position in Precision Oncology?

Simply Wall St.
·
Oct 20, 2025

Natera Inc: Successful Imvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients

THOMSON REUTERS
·
Oct 20, 2025

Natera Reports IMvigor011 Trial Shows 41% Survival Boost With Signatera-Guided Bladder Cancer Treatment

Reuters
·
Oct 20, 2025

Roche’s Tecentriq Significantly Improves Survival in ctDNA-Guided Bladder Cancer Study

Reuters
·
Oct 20, 2025

DE, RKLB, NTRA, QSI: Cathie Wood Loads Up on Deere and ATAI, Trims Stakes in Rocket Lab and Biotech Stocks

TIPRANKS
·
Oct 18, 2025

Natera Inc. Director and Co-Founder Jonathan Sheena Reports Disposal of Common Shares

Reuters
·
Oct 18, 2025

Natera Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Oct 14, 2025

Canaccord Genuity Sticks to Their Buy Rating for Natera (NTRA)

TIPRANKS
·
Oct 14, 2025

Signatera Validation and EXPAND Trial Progress Could Be a Game Changer for Natera (NTRA)

Simply Wall St.
·
Oct 13, 2025

Natera to present 14 studies to be presented at ESMO Congress

TIPRANKS
·
Oct 13, 2025

BRIEF-Natera Says To Present 14 Studies At ESMO, Including Imvigor011 Oral Presentation

Reuters
·
Oct 13, 2025